NCT04820686Phase 2Terminated

A Study Evaluating Treatment Regimens Containing Vebicorvir (ABI-H0731) in Participants With Chronic Hepatitis B Infection

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2023-03-30Actual

Enrollment · participants65Actual

Source updated2023-11-14Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Study details

Conditions studied

Chronic Hepatitis B

Treatments or interventions studied

VBRDrugAlso known as Vebicorvir, ABI-H0731
AB-729Drug
SOC NrtIDrugAlso known as Entecavir (ETV), Tenofovir disoproxil fumarate (TDF), Tenofovir alafenamide (TAF)

Primary outcomes · main study measures

Read the study measures

measure: Number of Participants With One or More Adverse Events (AEs); timeFrame: AEs were collected from the time of signing the informed consent until the final follow-up visit, up to 96 weeks.; measure: Number of Participants With Premature Treatment Discontinuation Due to AEs; timeFrame: AEs were collected from the time of signing the informed consent until the final follow-up visit, up to 96 weeks.; measure: Number of Participants With One or More Abnormal Laboratory Result; timeFrame: Laboratory results were collected from the time of signing the informed consent until the study was early terminated, up to 96 weeks.

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history